The goal of the Women's Oncology Program (WON) is: (1) to accelerate the pace and expand the range of fundamental discovery research about women's cancers and (2) to facilitate the translation of new scienfific findings into the clinic. WON Members study novel pathways by which hormones and growth factors regulate growth and metastasis of women's cancers;identify potential new therapeufic targets or prognostic indicators for response or resistance to therapy;and perform clinical trials to test efficacy of therapeutic agents in treating these cancers. Program leadership has organized WON around three research themes: (1) steroid hormone action and steroid-dependent cancers;(2) growth factor and cytokine promotion of tumor development and metastasis;and (3) invesfigator-initiated clinical research and development of novel clinical research tools. Professor of Medicine and Physiology Margaret A. Shupnik, PhD, and Professor of Medicine Paula M. Fracasso, MD, PhD, lead the Program. Dr. Shupnik has expertise in molecular endocrinology and estrogen receptor action, and Dr. Fracasso is an experienced clinical trialist in women's oncology. The Program represents a wide variety of expertise: 22 Members from nine departments in the schools of Medicine and of Engineering, and six Associate Members. With critical CCSG help, seven WON Members have joined the University of Virginia (UVA) since the last renewal, and two Members have been retained. The following areas of support have enabled the success of WON research initiatives, which have become increasingly cancer focused and interactive: funding for faculty recruitment and retention;funding for informafion exchange forums, such as the CC Seminar Series, WON research meetings, and the Program Retreat;Cancer Center Pilot Project Funds;and support from the UVA Cancer Center Shared Resources. Total extramural funding for the Program exceeds $10.5 million, including nearly $5 million from the Nafional Cancer Institute (NCI). Over the past five years, WON Members have published 317 Program-relevant papers of which 29% were inter-Programmatic and 21% were intra-Programmatic.

Public Health Relevance

; The goal of the Women's Oncology Program (WON) is: (1) to accelerate the pace and expand the range of fundamental discovery research about women's cancers and (2) to facilitate the translation of new scientific findings into the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-21
Application #
8231125
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-02-01
Project End
2017-01-31
Budget Start
2012-06-05
Budget End
2013-01-31
Support Year
21
Fiscal Year
2012
Total Cost
$28,732
Indirect Cost
$10,509
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Pfister, Katherine; Pipka, Justyna L; Chiang, Colby et al. (2018) Identification of Drivers of Aneuploidy in Breast Tumors. Cell Rep 23:2758-2769
Carhart, Miev Y; Schminkey, Donna L; Mitchell, Emma M et al. (2018) Barriers and Facilitators to Improving Virginia's HPV Vaccination Rate: A Stakeholder Analysis With Implications for Pediatric Nurses. J Pediatr Nurs 42:1-8
Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409
Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :

Showing the most recent 10 out of 539 publications